Expanding Access to Advanced Biologics
Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma), one of the fastest-growing pharmaceutical companies in the Middle East and Africa, has announced a strategic commercialization agreement with Bio-Thera Solutions, Ltd. Bio-Thera is a global biopharmaceutical company known for innovative therapies and biosimilars.
Under this agreement, Jamjoom Pharma will gain exclusive rights to commercialize BAT2306. This drug is a proposed biosimilar to Novartis’ Cosentyx® (secukinumab). The rights cover the entire Middle East and North Africa (MENA) region.
Roles in the Partnership: Jamjoom Pharma will manage:
- Regulatory submissions
- Market access
- Commercialization in the MENA region
Meanwhile, Bio-Thera will handle product development and global manufacturing at its advanced facilities in Guangzhou, China.
Commitment to Patient Care
Tarek Hosni, Chief Executive Officer of Jamjoom Pharma, emphasized the importance of this deal.
“This collaboration is a strategic milestone for Jamjoom Pharma and a testament to our mission of broadening access to advanced biologics in the MENA region. By joining forces with Bio-Thera, we are combining world-class biosimilar development with Jamjoom’s regional expertise, strong commercial capabilities, and commitment to affordable therapies.”
He added that the agreement strengthens Jamjoom’s leadership in the biopharmaceutical sector and reinforces its role in improving patient outcomes.
Bio-Thera’s Perspective
Bert Thomas, Senior Vice President of Business Development at Bio-Thera, also highlighted the partnership.
“Bio-Thera is committed to bringing affordable medicines to patients in need around the world. Partnering with Jamjoom Pharma to bring BAT2306 to patients in the MENA region is a demonstration of that commitment. We are proud to collaborate with Jamjoom Pharma and look forward to success.”
A Milestone for Healthcare in MENA
This deal marks a new step forward in providing patients across the Middle East and North Africa with affordable access to advanced biologic treatments. The partnership is set to expand the availability of biosimilars and improve long-term healthcare outcomes.
